Dentsply Sironaの空売り状況は、投資家がDentsply Sironaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Dentsply Sirona (NASDAQ:XRAY) 株価情報, 空売り情報

Dentsply Sirona

Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).

Dentsply Sirona Inc

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo analyst Vik Chopra initiated coverage on Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with an Equal-Weight rating and announced a price target of $80. Henry Schein shares closed at $77.62 on Thursday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Michael Okunewitch initiated coverage on Mainz Biomed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) with a Buy rating and announced a price target of $14. Mainz Biomed shares closed at $6.53 on Thursday. <a href="https://www.benzinga.com/quote/MYNZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst David Williams initiated coverage on Analog Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy rating and announced a price target of $245. Analog Devices shares closed at $209.34 on Thursday. <a href="https://www.benzinga.com/quote/ADI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Vik Chopra initiated coverage on Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with an Overweight rating and announced a price target of $255. Align Tech shares closed at $204.89 on Thursday. <a href="https://www.benzinga.com/quote/ALGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street analyst Jaeson Schmidt initiated coverage on BK Technologies Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) with a Buy rating and announced a price target of $40. BK Technologies shares closed at $28.97 on Thursday. <a href="https://www.benzinga.com/quote/BKTI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADI stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-1024x585.png" alt="" class="wp-image-783129" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ALGN

BKTI

CRSP

HSIC

MYNZ

XRAY

This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wells Fargo analyst Vik Chopra initiates coverage on Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Equal-Weight rating and announces Price Target of $20.

Price Target

Wells Fargo Initiates Coverage On Dentsply Sirona with Equal-Weight Rating, Announces Price Target of $20

Rumors

Watching DENTSPLY SIRONA; Traders Circulate Unconfirmed Rumor An Activist Has Taken A Position And There May Be A Bidder For The Company

Needham analyst David Saxon reiterates Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and maintains $25 price target.

Reiteration

Needham Reiterates Buy on Dentsply Sirona, Maintains $25 Price Target

General

Dentsply Sirona shares are trading higher after the company initiated a review of strategic alternatives for its Wellspect Healthcare business.

Dentsply Sirona Initiates Review Of Strategic Alternatives For Its Wellspect Healthcare Business

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $23.0, along with a high estimate of $27.00 and a low estimate of $20.00. Highlighting a 25.4% decrease, the current average has fallen from the previous average price target of $30.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1738238452_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Dentsply Sirona among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dentsply Sirona. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Dentsply Sirona's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dentsply Sirona analyst ratings.</a>
<h2>Unveiling the Story Behind Dentsply Sirona</h2>
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
<h3>Key Indicators: Dentsply Sirona's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Dentsply Sirona's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 0.42%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dentsply Sirona's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -51.95%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dentsply Sirona's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -17.79%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.31%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Dentsply Sirona's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.93, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Dentsply Sirona Stock: Analyst Perspectives (8 Ratings)

Needham analyst David Saxon maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and raises the price target from $23 to $25.

Needham Maintains Buy on Dentsply Sirona, Raises Price Target to $25

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird raised the price target for Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) from $85 to $89. Baird analyst Luke Junk maintained an Outperform rating. Amphenol shares closed at $77.84 on Wednesday. <a href="https://www.benzinga.com/quote/APH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt increased Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) price target from $100 to $115. Rosenblatt analyst Catharine Trebnick maintained a Buy rating. Fortinet shares closed at $98.24 on Wednesday. <a href="https://www.benzinga.com/quote/FTNT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised the price target for Tractor Supply Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) from $60 to $62. Mizuho analyst David Bellinger maintained an Outperform rating. Tractor Supply shares closed at $57.47 on Wednesday. <a href="https://www.benzinga.com/quote/TSCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co raised the price target for Nuvation Bio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) from $10 to $11. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. Nuvation Bio shares closed at $2.65 on Wednesday. <a href="https://www.benzinga.com/quote/NUVB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan boosted International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) price target from $227 to $233. JP Morgan analyst Brian Essex maintained a Neutral rating. IBM shares settled at $223.26 on Wednesday. <a href="https://www.benzinga.com/quote/IBM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) price target from $53 to $65. Piper Sandler analyst Alexander Potter upgraded the stock from Underweight to Neutral. Aptiv shares closed at $62.73 on Wednesday. <a href="https://www.benzinga.com/quote/APTV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods increased Nicolet Bankshares, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIC#NYSE">NIC</a>) price target from $110 to $115. Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintained a Market Perform rating. Nicolet Bankshares shares closed at $110.22 on Tuesday.  <a href="https://www.benzinga.com/quote/NIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sach cut the price target for Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from $286 to $280. Goldman Sachs analyst Michael Ng maintained a Buy rating. Apple shares settled at $223.83 on Wednesday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) price target from $30 to $20. Jefferies analyst Glen Santangelo downgraded the stock from Buy to Hold. DENTSPLY SIRONA shares closed at $19.36 on Wednesday. <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities increased Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) price target from $660 to $710. B of A Securities analyst Justin Post maintained a Buy rating. Meta shares closed at $623.50 on Wednesday. <a href="https://www.benzinga.com/quote/META/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

AAPL

APTV

FTNT

NUVB

TSCO

Apple To $280? Here Are 10 Top Analyst Forecasts For Thursday

Jefferies analyst Glen Santangelo downgrades Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) from Buy to Hold and lowers the price target from $30 to $20.

Downgrades

Jefferies Downgrades Dentsply Sirona to Hold, Lowers Price Target to $20

DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) today announced that the Company plans to refocus the Byte business model around treatments that include expanded in-person dentist oversight. The Company is evaluating the go-to-market business and economic model and expects to leverage collaborative direct-to-consumer ("DTC") demand generation with dentists using Byte core competencies, expand digital customer journey management across the aligner portfolio, and utilize Byte skillsets to further enhance customer service and marketing across the Company. In connection with this review, Dentsply Sirona is not reinstating the at-home Byte Aligner Systems and Impression Kits but will continue to provide support for non-contraindicated Byte Aligner patients currently undergoing treatment. Dentsply Sirona will continue to work with regulatory authorities and obtain any necessary clearances prior to any market launch.

DENTSPLY SIRONA Announces Refocus Of Byte Business Model On In-Person Dentist Oversight, Evaluating Direct-To-Consumer Collaboration And Digital Management, Support Continues For Existing Byte Aligner Patients, Regulatory Clearances Ongoing

Evercore ISI Group analyst Elizabeth Anderson downgrades Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) from Outperform to In-Line and announces $20 price target.

Evercore ISI Group Downgrades Dentsply Sirona to In-Line, Announces $20 Price Target

Morgan Stanley analyst Erin Wright maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Overweight and lowers the price target from $30 to $23.

Morgan Stanley Maintains Overweight on Dentsply Sirona, Lowers Price Target to $23

On Wednesday,&nbsp;Patient Square Capital, a healthcare investment firm, agreed to acquire&nbsp;Patterson Companies, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>), a dental and animal health product distributor, for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42433177/patterson-companies-announces-definitive-agreement-to-be-acquired-by-patient-square-capital-for-31" rel="noreferrer noopener">approximately $4.1 billion</a>.
During its second-quarter earnings release, the company announced it is exploring strategic options, including a sale or merger,&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42342667/dental-supplies-patterson-companies-evaluates-strategic-alternatives-after-mixed-q2-earnings-amid-challenging-end-market-environment" rel="noreferrer noopener">to boost shareholder value</a>.
William Blair notes that based on Patient Square Capital&#8217;s portfolio, which doesn&#8217;t include dental or animal health companies, regulatory hurdles for this deal are unlikely.
Additionally, the analyst&#8217;s dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.
The valuation analysis includes Align Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), Dentsply Sirona Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), Henry Schein Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>), Envista Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) and Europe-listed Straumann Holding.
William Blair writes that most dental companies they cover are trading at or near their lowest valuations in 15 years, as investor interest has declined due to ongoing macroeconomic challenges.
Most recently,&nbsp;Dentsply Sirona revised its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary&nbsp;suspension of sales, marketing, and shipments of Byte Aligners <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814727/dentsply-sirona-stock-sinks-on-dismal-2024-guidance-blames-macroeconomic-competitiv" rel="noreferrer noopener">and Impression Kits</a>.
Henry Schein&#8217;s third-quarter global dental segment sales were $1.9 billion, down 1.6%, and medical segment sales increased by 2.9% (down 4.8% internally) <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752173/henry-schein-q3-earnings-sees-recovery-from-cyber-incident-says-dental-equipment-business-shows-sta" rel="noreferrer noopener">to $1.1 billion</a>.
While it&#8217;s still early to gauge investor reactions, the analyst is considering whether Patterson&#8217;s acquisition might stabilize valuations and boost demand in the dental sector.
The analyst writes the move could support valuations and signal a potential recovery in the market, making many dental stocks appealing from a risk/reward perspective.
Among these, William Blair sees Align as having the greatest potential for stock growth, driven by improving market conditions and gains in both earnings and valuation.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42465586/gevo-and-lg-chem-push-ahead-on-eto-commercialization-for-sustainable-aviation-and-bio-propylene-markets" target="_blank" rel="noreferrer noopener">Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Large Cap

Health Care

NVST

PDCO

What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XRAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$40.5K</td>
<td>3.2K</td>
<td>2.1K</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$30.0K</td>
<td>8.4K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$50.00</td>
<td>$86.8K</td>
<td>9.6K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LFST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.00</td>
<td>$35.0K</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$42.00</td>
<td>$33.0K</td>
<td>536</td>
<td>281</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$95.00</td>
<td>$44.7K</td>
<td>439</td>
<td>161</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$145.00</td>
<td>$26.1K</td>
<td>2.0K</td>
<td>95</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$470.00</td>
<td>$33.2K</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$65.00</td>
<td>$29.1K</td>
<td>278</td>
<td>11</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$470.00</td>
<td>$29.0K</td>
<td>1</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For XRAY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), we notice a call option trade that happens to be neutral, expiring in 128 day(s) on April 17, 2025. This event was a transfer of 225 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $40.5K, with a price of $180.0 per contract. There were 3202 open contracts at this strike prior to today, and today 2122 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 400 contract(s) at a $9.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $75.0 per contract. There were 8401 open contracts at this strike prior to today, and today 1738 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 482 contract(s) at a $50.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $86.8K, with a price of $180.0 per contract. There were 9650 open contracts at this strike prior to today, and today 1214 contract(s) were bought and sold. 
• Regarding LFST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>), we observe a call option trade with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 500 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $70.0 per contract. There were 1847 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on January 17, 2025. This event was a transfer of 314 contract(s) at a $42.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $33.0K, with a price of $105.0 per contract. There were 536 open contracts at this strike prior to today, and today 281 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 101 day(s) on March 21, 2025. This event was a transfer of 50 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $44.7K, with a price of $895.0 per contract. There were 439 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 67 contract(s) at a $145.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $26.1K, with a price of $390.0 per contract. There were 2061 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a call option trade that happens to be neutral, expiring in 283 day(s) on September 19, 2025. This event was a transfer of 20 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $33.2K, with a price of $1660.0 per contract. There were 22 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be neutral, expiring in 402 day(s) on January 16, 2026. This event was a transfer of 11 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.1K, with a price of $2654.0 per contract. There were 278 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on January 24, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $2900.0 per contract. There were 1 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFST

RXRX

VKTX

VRTX

10 Health Care Stocks With Whale Alerts In Today's Session

In the latest quarter, 7 analysts provided ratings for Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.86, a high estimate of $36.00, and a low estimate of $21.00. A decline of 19.82% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1733321040_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Dentsply Sirona among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dentsply Sirona. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Dentsply Sirona's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dentsply Sirona's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dentsply Sirona analyst ratings.</a>
<h2>Delving into Dentsply Sirona's Background</h2>
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
<h3>Understanding the Numbers: Dentsply Sirona's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Dentsply Sirona's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.42% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Dentsply Sirona's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -51.95%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dentsply Sirona's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -17.79%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Dentsply Sirona's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.31%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Dentsply Sirona's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.93, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Dentsply Sirona

Mizuho analyst Steven Valiquette initiates coverage on Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Neutral rating and announces Price Target of $21.

Mizuho Initiates Coverage On Dentsply Sirona with Neutral Rating, Announces Price Target of $21

UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $35 to $27.

UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $27

DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) today announced that Herman V. Cueto, a seasoned healthcare executive, has been appointed Interim Chief Financial Officer, effective immediately. He brings over two decades of experience leading and working in finance organizations across the healthcare industry. Mr. Cueto will oversee the finance organization while Dentsply Sirona completes its ongoing search for the Company's next CFO.

Management

DENTSPLY SIRONA Appoints Herman V. Cueto As Interim Chief Financial Officer, Effective Immediately

Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and lowers the price target from $36 to $24.

Barrington Research Maintains Outperform on Dentsply Sirona, Lowers Price Target to $24

Press Releases

The Gross Law Firm Notifies Shareholders of Dentsply Sirona Inc.(XRAY) of a Class Action Lawsuit and an Upcoming Deadline

Legal

Final XRAY Deadline Reminder: January 27, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DENTSPLY SIRONA

XRAY LAWSUIT ALERT: Levi & Korsinsky Notifies Dentsply Sirona Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Dentsply Sirona to Host Fourth Quarter and Full Year 2024 Conference Call on February 27th

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DENTSPLY SIRONA Inc. - XRAY

DENTSPLY ALERT: Bragar Eagel & Squire, P.C. is Investigating DENTSPLY SIRONA Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Dentsply Sirona

空売り

Dentsply Sirona (NASDAQ:XRAY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル